Research
Hormonal
Semaglutide treatment resulted in a 17% reduction in new-onset atrial fibrillation (AF) incidence compared to controls.
Semaglutide may be an effective treatment option for reducing the risk of new-onset AF in patients.
StrongSupportsmedium confidence
Semaglutide treatment resulted in a 17% reduction in AF incidence compared to controls (OR 0.83, 95% CI 0.70-0.98, p = 0.03).
Why this rating
Based on a meta-analysis of 26 randomized controlled trials.
Source
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials
Arturo Cesaro et al. · European Journal of Preventive Cardiology · 2025
Meta-analysisCited 29×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →